# Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

> **NCT05876312** · PHASE1,PHASE2 · RECRUITING · sponsor: **ADARx Pharmaceuticals, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria (PNH)

## Interventions

- **DRUG:** ADX-038
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05876312
- **Lead sponsor:** ADARx Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-07
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05876312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05876312, "Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05876312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*